IP Library Granted Patent US 9,125,820
Granted Patent B2
US 9,125,820 · App. 14/286,033 · Granted Sep 8, 2015

Lipids, lipid complexes and use thereof

Inventors: Oliver Keil (Glienicke/Nordbahn, DE); Jörg Kaufmann (Berlin, DE); Ansgar Santel (Berlin, DE)
Assignee: SILENCE THERAPEUTICS GMBH
A61K9/127A61K9/1271A61K9/1272A61K31/713A61K47/183A61K47/186A61K47/48046A61K47/48815C07C209/50C07C279/14C12N15/111C12N15/1138C12N2310/14C12N2310/321C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,125,820
App. No.
14/286,033
Granted
Sep 8, 2015
Kind
B2
Abstract

The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), wherein R 1 and R 2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R 3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II), wherein m is any integer from 1 to 3 and Y − is a pharmaceutically acceptable anion.

Claims (22)

1. A method for transferring a pharmaceutically active compound into a cell or across a membrane or cell membrane, comprising the following steps:

providing the cell or the membrane;

providing a compound according to formula (I),

wherein R 1 and R 2 are each and independently an alkyl group;

n is any integer between 1 and 4;

R 3 is an acyl selected from the group consisting of lysyl, ornithyl, 2,4-diaminobutyryl,

histidyl and an acyl moiety according to formula (II),

wherein m is any integer from 1 to 3 and

Y − is a pharmaceutically acceptable anion;

providing the pharmaceutically active compound; and

contacting the cell or the membrane with the pharmaceutically active compound and said compound of formula (I).

2. The method according to claim 1 , wherein said compound of formula (I) is provided in the form of a composition comprising a carrier and said compound of formula (I).

3. The method according to claim 1 , wherein the method further comprises detecting the pharmaceutically active compound in the cell and/or beyond the membrane.

4. A method of delivering a reagent to a cell, comprising contacting said cell with a compound according to formula (I),

wherein R 1 and R 2 are each and independently an alkyl group;

n is any integer between 1 and 4;

R 3 is an acyl selected from the group consisting of lysyl, ornithyl, 2,4-diaminobutyryl,

histidyl and an acyl moiety according to formula (II),

wherein m is any integer from 1 to 3 and

Y − is a pharmaceutically acceptable anion and a reagent selected from the group consisting of a peptide, a protein, an oligonucleotide, a polynucleotide and a nucleic acid.

5. The method according to claim 4 , wherein said cell is a human cell.

6. The method according to claim 5 , wherein said cell is an endothelial cell.

Assignments (2)
CHANGE OF NAME Recorded Jan 15, 2015
From: SILENCE THERAPEUTICS AG
To: SILENCE THERAPEUTICS GMBH
Reel/Frame 034767/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2014
From: KEIL, OLIVER; KAUFMANN, JORG; SANTEL, ANSGAR
To: SILENCE THERAPEUTICS AG
Reel/Frame 032971/0931 →
Priority Claims (2)
EP 04010700 · May 5, 2004 · regional
EP 04030847 · Dec 27, 2004 · regional
Continuity (4)
Continuation 13742700 · Jan 16, 2013
Division 13230085 · Sep 12, 2011
Division 11579700
Related Publication 20140329885A1 · Nov 6, 2014